Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zynerba Pharma CS (NQ: ZYNE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zynerba Pharma CS

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Why Shares of Harmony Bioscience Are Falling on Friday
The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia. 
Via The Motley Fool
New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies
Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc. 
Via Benzinga
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Bearish Sentiment Across The Cannabis Space - Check Full Movers For September 26, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For September 18, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment... 
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sovos Brands, Inc. (Nasdaq - SOVO), Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Cannabis Stock Movers For August 18, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From August 16, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Occidental Petroleum To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Wednesday
Piper Sandler lowered the price target for Riskified Ltd. (NYSE: RSKD) from $8 to $7. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Riskified shares gained 12% to close at $4.77... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Chindata Group Holdings Limited (Nasdaq - CD), Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID)
From Brodsky & Smith LLC
Via GlobeNewswire
Cannabis Stock Gainers And Losers From August 14, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 90 points on Monday. The Dow traded down 0.14% to 35,232.62 while the NASDAQ rose 0.66% to 13,735.42. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
US Stocks Turn Higher; BioXcel Therapeutics Shares Plummet
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 80 points on Monday. The Dow traded up 0.01% to 35,284.34 while the NASDAQ rose 0.64% to 13,732.05.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Health Care Company Harmony Biosciences Announces Acquisition of Zynerba Pharmaceuticals
Via Benzinga
Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today?
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares are skyrocketing Monday after Harmony Biosciences (NASDAQ: HRMY) announced it will 
Via Benzinga
Dow Falls 50 Points; Monday.com Posts Upbeat Results
U.S. stocks traded mostly lower this morning, with the Dow Jones falling around 50 points on Monday. Following the market opening Monday, The Dow traded down 0.14% to 35,230.38 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
ZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Marijuana Stock Movers For August 9, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT 
From Zynerba Pharmaceuticals, Inc.
Via GlobeNewswire
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.